SCHEMBL20180015

SCHEMBL20180015

ICC1C2CC3CC(C2)CC1C3

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
CYP2C9 P11712 1/20 0.38
CXCR3 P49682 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21422283 0.73
SCHEMBL21509287 0.69
SCHEMBL2825487 0.69 HSD11B1 (0.44) HSD11B1CYP2C9CXCR3
SCHEMBL21650459 0.69 HSD11B1 (0.44) HSD11B1CYP2C9CXCR3
SCHEMBL678974 0.69 HSD11B1 (0.50) HSD11B1CYP2C9CXCR3
SCHEMBL22483779 0.69 HSD11B1 (0.44) HSD11B1CYP2C9CXCR3
SCHEMBL21048748 0.69 HSD11B1 (0.50) HSD11B1CYP2C9CXCR3
SCHEMBL22486360 0.69
SCHEMBL16567928 0.69 HSD11B1 (0.50) HSD11B1CYP2C9CXCR3
SCHEMBL906308 0.69 HSD11B1 (0.44) HSD11B1CYP2C9CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230337524-A1 ORGANOMETALLIC COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-10-19 US disclosed
US-10400003-B2 Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2019-09-03 US disclosed
US-20180141969-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10400003-B2 Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound ORC3, LEF1, OCIAD1 HSD11B1 670/4885CYP2C9 342/4885CXCR3 3762/4885
US-20230337524-A1 ORGANOMETALLIC COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING THE SAME LAGE3, L1CAM, LEF1 HSD11B1 1431/4885CYP2C9 523/4885CXCR3 3418/4885
US-20180141969-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND ORC3, LEF1, OCIAD1 HSD11B1 670/4885CYP2C9 342/4885CXCR3 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.